Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.74 |
| ▸ | FAAH | O00519 | 4/20 | 0.64 |
| ▸ | RAF1 | P04049 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18808856 | 0.86 | PARP10 (0.57) | EPHX2FAAHRAF1MEN1KMT2A | |
| SCHEMBL22381961 | 0.85 | EPHX2 (1.00) | EPHX2FAAHRAF1 | |
| SCHEMBL20390673 | 0.82 | EPHX2 (0.77) | EPHX2FAAHRAF1NPC1RAB9A | |
| SCHEMBL27004196 | 0.82 | EPHX2 (0.77) | EPHX2FAAHRAF1 | |
| SCHEMBL15624829 | 0.82 | EPHX2 (0.77) | EPHX2FAAHRAF1NPC1RAB9A | |
| SCHEMBL3194212 | 0.81 | EPHX2 (1.00) | EPHX2FAAHNPC1RAB9AEPHX1 | |
| SCHEMBL3182099 | 0.81 | EPHX2 (1.00) | EPHX2FAAHNPC1RAB9AEPHX1 | |
| SCHEMBL3191141 | 0.81 | EPHX2 (1.00) | EPHX2FAAHNPC1RAB9AEPHX1 | |
| SCHEMBL3192513 | 0.81 | EPHX2 (1.00) | EPHX2FAAHNPC1RAB9AEPHX1 | |
| SCHEMBL3194206 | 0.81 | EPHX2 (1.00) | EPHX2FAAHNPC1RAB9AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485107-B2 | Methods for the prevention or treatment of cytokine storm | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| WO-2020146770-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF CYTOKINE STORM, AND FOR PREVENTING DISEASES OR CONDITIONS CAUSED BY CYTOKINE STORM | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12485107-B2 | Methods for the prevention or treatment of cytokine storm | TNF, PTGES2, IL2 | EPHX2 13/4885FAAH 16/4885RAF1 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.